Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLS4/Ritonavir in Chronic Hepatitis B
NCT03638076Phase 2Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Jul 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mofesertib in Chronic Hepatitis B (CHB) (2 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Mean value of HBV DNA decreased from baseline at 49 weeks and Adverse events at 49 weeks. Started Jul 2017; status: completed.
02
Drugs
mofesertib
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03638076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03638076.